Oxytocin — Labor induction, postpartum hemorrhage
Labor induction, postpartum hemorrhage, and off-label intranasal research
- Class
- Cyclic nonapeptide hormone (posterior-pituitary neuropeptide)
- Status
- FDA-approved prescription drug (Pitocin / Syntocinon) for labor induction, labor augmentation, and postpartum hemorrhage control. Intranasal use for psychiatric, social, sexual, or behavioral indications is off-label and not FDA-approved.
- Best-supported effect
- Uterine contraction for labor induction/augmentation and control of postpartum hemorrhage in obstetric care; with mechanistic and animal support for central effects on social cognition, stress, and bonding via the OXTR receptor.
- Main caveat
- Off-label intranasal use for autism, PTSD, social anxiety, postpartum depression, and sexual function is not FDA-approved; the SOARS-B-pattern autism trial reported a null primary outcome and the broader behavioral literature is mixed and context-dependent.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Cyclic nonapeptide hormone (posterior-pituitary neuropeptide)
Evidence tier: Approved drug
Status: FDA-approved prescription drug (Pitocin / Syntocinon) for labor induction, labor augmentation, and postpartum hemorrhage control. Off-label intranasal use for psychiatric, social, and sexual indications is not FDA-approved.
Best-supported effect: Uterine contraction for labor induction/augmentation and control of postpartum hemorrhage in obstetric care; with mechanistic and animal support for central effects on social cognition, stress, and bonding via the OXTR receptor.
Main caveat: Off-label intranasal use for autism, PTSD, social anxiety, postpartum depression, and sexual function is not FDA-approved; the large SOARS-B autism trial reported a null result on the primary outcome and the broader behavioral/social-cognition literature is mixed and context-dependent.
What this is
Oxytocin is a 9-amino-acid cyclic peptide hormone with a disulfide bridge between Cys1 and Cys6, synthesized in the hypothalamus (paraventricular and supraoptic nuclei) and released from the posterior pituitary. It was the first peptide hormone to be chemically synthesized — by Vincent du Vigneaud at Cornell in 1953 — work that won the 1955 Nobel Prize in Chemistry. Synthetic oxytocin was approved by the FDA as Pitocin in 1962 for obstetric use and is on the WHO Model List of Essential Medicines.
Two largely separate clinical contexts dominate the literature: an established obstetric role (IV / IM oxytocin for labor induction, augmentation, and postpartum hemorrhage) and an off-label research-driven role (intranasal oxytocin studied for autism spectrum disorder, PTSD, social anxiety, postpartum depression, and sexual function). The peptide's identity as a defined drug rests on the obstetric approval; the popular "love hormone" framing reflects research interest rather than approved use.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Approved | FDA-approved obstetric indications (labor induction/augmentation, postpartum hemorrhage); multiple post-2010 RCTs in obstetrics extracted from the available literature |
| Human | Phase II / mixed | Off-label intranasal trials in autism, PTSD, social anxiety, postpartum depression, alcohol-use behavior, schizophrenia neurocognition, obesity, and sexual function — described in the available literature as mixed-to-disappointing, with the SOARS-B autism trial reported as a null result on its primary outcome |
| Animal | Comprehensive | available literature describes oxytocin biology as one of the most studied neuropeptide systems; detailed individual animal study data are not individually extracted |
| In vitro | Mechanistic | OXTR receptor characterization (Gq-coupled GPCR) supporting uterine, mammary, and CNS mechanism; not individually extracted as separate assay rows |
| Mechanism | Strong | OXTR signaling in uterus, mammary tissue, amygdala, hippocampus, nucleus accumbens, hypothalamus, and prefrontal cortex is well characterized in the available literature |
A 2025 systematic review cited in the available literature emphasizes that intranasal oxytocin effects on social cognition are highly dose-, route-, sex-, and context-dependent, replacing earlier universal-prosocial framing.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Oxytocin (Pitocin) is effective for labor induction, labor augmentation, and control of postpartum hemorrhage | Supported | Human, FDA label and obstetric RCTs | High |
| Intranasal oxytocin is an effective treatment for autism spectrum disorder | Contradicted / not established | Human (Phase II) | High — the available literature reports the large SOARS-B trial as null on its primary social-withdrawal outcome, contradicting smaller earlier-trial signals |
| Intranasal oxytocin reliably enhances trust, bonding, and prosocial behavior in healthy users | Weak / context-dependent | Human (acute experimental) | Medium — acute effects are documented but described in the available literature as context-, sex-, dose-, and genotype-dependent, with in-group / out-group asymmetries |
| Intranasal oxytocin acutely reduces stress and amygdala reactivity in laboratory paradigms | Partially supported (acute, intranasal) | Human (acute fMRI / stress challenge) | Medium — translation to chronic anxiety-disorder treatment described as less successful in controlled trials |
| Intranasal oxytocin enhances orgasm and sexual function | Weak (small intranasal studies) | Human (small trials) | Low — small-trial signals only; magnitude in standard use described as unclear in the available literature |
| Intranasal oxytocin is FDA-approved for psychiatric, behavioral, or sexual indications | Contradicted | Regulatory (FDA) | High — available literature explicitly states no FDA approval exists for any non-obstetric indication |
| Oxytocin is "the love hormone" and exogenous administration reliably increases social connection | Contradicted / not established | Human (acute experimental) | High — available literature describes the simple-effect framing as not surviving contact with the broader literature |
The intranasal-trial evidence in this row set covers a different route, formulation context, and indication set than the FDA-approved IV / IM obstetric label; obstetric efficacy claims do not transfer to behavioral or psychiatric claims.
Exposure studied
This section reports exposure used in labels and human studies. It is not a personalized protocol.
| Context | Population | Exposure studied | Duration | Endpoint | Limitation |
|---|---|---|---|---|---|
| FDA label (Pitocin, labor induction/augmentation) | Adults in labor | IV infusion, started low and titrated upward to establish a contraction pattern (label-described titration regimen) | Episodic, tied to the obstetric event with continuous fetal and contraction monitoring | Establishment of an effective contraction pattern; delivery | IV obstetric use only; not transferable to non-obstetric exposure or routes |
| FDA label (Pitocin, postpartum hemorrhage) | Postpartum adults with uterine atony or hemorrhage risk | IM dose or dilute IV infusion per hemorrhage protocol | Situational, peri-/post-delivery | Control of postpartum bleeding / uterine tone | Obstetric emergency-use context only |
| Obstetric clinical trials (multiple post-2020 RCTs in available literature) | Pregnant or postpartum adults | Various IV / IM regimens compared with comparators (misoprostol, carbetocin, intermittent vs continuous induction) | Tied to delivery event | Hemorrhage, induction success, neonatal outcomes, troponin, blood loss | Trials specific to obstetric outcomes; not extractable to non-obstetric claims |
| Intranasal research trials (autism, PTSD, social anxiety, postpartum depression, alcohol-use behavior, obesity, schizophrenia, healthy-volunteer paradigms) | Heterogeneous research populations | Intranasal oxytocin in research studies; exact regimens not individually extracted | Acute single-dose paradigms through chronic dosing for several weeks in some trials | Behavioral, neuroimaging, biomarker, and disorder-specific endpoints | Not FDA-approved; intranasal product is compounded or research-formulated; CNS penetration debated; results described as mixed-to-disappointing |
| Intrathecal research trials (post-surgical pain / recovery) | Adults undergoing hip arthroplasty or related procedures | Intrathecal oxytocin in trial protocols; exact regimens not individually extracted | Peri-operative | Recovery speed, vasopressor requirements, neuropathic pain | Investigational route, not approved; small trial set |
Safety signals
| Signal | Evidence context | Notes |
|---|---|---|
| Uterine hyperstimulation | IV obstetric label / human trials | Reason for continuous fetal and contraction monitoring during labor induction |
| Water intoxication, hyponatremia, seizure (at prolonged high IV doses) | IV obstetric label / human trials | Source describes oxytocin as having antidiuretic activity at high doses; obstetric protocols restrict total fluid volume and monitor electrolytes |
| Severe hypertension when combined with vasoconstrictor sympathomimetics, ergot alkaloids, or caudal-block anesthesia | IV obstetric label | Source-bundle interaction signal; described as a clinically significant obstetric drug interaction |
| Hypersensitivity to oxytocin or formulation components (e.g., chlorobutanol preservative) | IV obstetric label | Source-bundle label safety exclusion |
| Use contraindicated in cephalopelvic disproportion, unfavorable fetal position, prior classical uterine incision, hyperactive uterine patterns, fetal distress where delivery is not imminent | IV obstetric label | Label safety exclusions for obstetric IV use |
| Nasal irritation, transient nausea, headache | Intranasal research studies (off-label) | Source-bundle description of acute-tolerability profile; long-term controlled safety data outside obstetric context described as more limited |
| Long-term effects of chronic intranasal exposure on endogenous OXTR signaling | Long-term unknown | available literature reports this as a theoretical concern raised in the research literature but not resolved |
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Approved prescription drug | Pitocin / oxytocin injection approved 1962 for labor induction, labor augmentation, and postpartum hemorrhage control. No other FDA-approved indications. Intranasal use for behavioral/psychiatric indications is off-label; intranasal oxytocin in the US is obtained via compounding pharmacy prescription or research-chemical channels. |
| EU / UK / Canada / Australia / Japan | Approved obstetric medicine | available literature describes oxytocin as approved as an obstetric medicine across major Western markets; intranasal off-label status is similar to the US; detailed country-specific indication and dosing language not separately extracted in this card. |
| WHO | On the WHO Model List of Essential Medicines | available literature describes oxytocin as an essential medicine for obstetric use. |
| WADA | Not prohibited | Source-bundle description; not listed on the WADA Prohibited List as of source date. |
Clinical trials
the available literature bundle lists numerous post-2010 randomized controlled trials and reviews relevant to oxytocin. Individual trial registry IDs (e.g., NCT numbers) are not present in the available literature and have not been added to this card. The bundle covers obstetric trials (induction strategies, postpartum hemorrhage prevention, comparator agents, neonatal morbidity), intranasal trials in autism (including chronic-administration trials and the SOARS-B-pattern null finding cited in the available literature), PTSD, alcohol-use behavior and intimate partner aggression, schizophrenia neurocognition, postpartum depression, social anxiety, obesity, sexual experience, intrathecal pain and recovery, and hypopituitarism. Detailed per-trial registry data, enrollment, and result rows are not individually extracted; see References for the trial citations present in the available literature.
Mechanism
Oxytocin acts as an agonist at the oxytocin receptor (OXTR), a Gq-coupled G-protein-coupled receptor. Peripherally, OXTR activation on uterine smooth muscle drives contraction, and OXTR activation on mammary myoepithelial cells drives milk ejection — the basis for the FDA-approved obstetric uses. Centrally, OXTR is distributed across the amygdala, hippocampus, nucleus accumbens, prefrontal cortex, hypothalamus, and brainstem; signaling at these sites is described in the available literature as modulating amygdala reactivity to threat, social-salience processing, HPA-axis stress response, autonomic tone, and behaviors related to pair bonding, sexual response, and social cognition.
The intranasal route is hypothesized to deliver peptide to the CNS via olfactory and trigeminal nerve pathways. The fraction of intranasal oxytocin that reaches brain tissue versus acting peripherally or via vagal afferents is debated in the available literature and is named explicitly as a foundational uncertainty for behavioral-trial interpretation. Effects on social cognition are described as context-, sex-, dose-, and genotype-dependent rather than as a uniform prosocial signal.
Chemistry
| Field | Value |
|---|---|
| Amino-acid sequence | Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (CYIQNCPLG) |
| Length | 9 amino acids |
| Topology | Cyclic (disulfide bridge between Cys1 and Cys6); C-terminal amide |
| Modifications | Disulfide bond Cys1–Cys6; C-terminal glycine amidation |
| Molecular formula | C43H66N12O12S2 |
| Molecular weight | ~1007.2 Da |
| CAS | 50-56-6 |
| Plasma half-life | 3–5 minutes (IV); intranasal CSF half-life reported as ~20 minutes in the available literature |
| Sequence confidence | Verified (consistent across available literature entries) |
Open questions
- CNS penetration after intranasal administration. Whether, and how much, intranasal oxytocin actually reaches the brain versus acting peripherally is described in the available literature as a foundational uncertainty that affects interpretation of every behavioral trial.
- Autism trial reconciliation. The large SOARS-B trial reported a null result on its primary social-withdrawal outcome, contradicting smaller earlier-trial signals; whether any responder subgroup can be identified and why earlier trials did not replicate at scale remain unresolved.
- Dose-response curves for behavioral endpoints. Whether standard 24 IU intranasal doses are sub-optimal, optimal, or supra-optimal for different behavioral outcomes is not well characterized; some evidence suggests inverted-U dose-response and sex differences.
- Long-term effects of chronic intranasal exposure. Whether chronic exogenous intranasal oxytocin downregulates OXTR expression or disrupts endogenous signaling has been raised as a theoretical concern in the available literature but is not resolved.
- Sex, genotype, and context effects. OXTR polymorphisms, participant sex, social context, and baseline attachment style appear to modulate response; trials that have not stratified by these factors may have obscured real effects.
- Postpartum depression and maternal-bonding trials. Most trials in this space are small and meaningful Phase III evidence is described as lacking despite promising signals.
- Behavioral / psychiatric Phase III translation. No off-label indication has reached a successful Phase III approval after 20+ years of Phase II research across autism, PTSD, social anxiety, and sexual function indications.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.947695255279541 | boltz-2 |
| ranking score | 0.8669947981834412 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.583 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸ lineage 1 parent
▸citationbibtex
@peptide{pep04424,
sequence = {CYIQNCPLG},
target = {oxtr},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}